Journal of Pediatric Hematology/Oncology最新文献_第10页

Pyrites: Adnexal Mass and Hypercalcemia in a Teenage Girl. 黄铁矿：一个少女的附件肿块和高钙血症。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-25 DOI: 10.1097/MPH.0000000000003223

Pritam Singha Roy, Jaydip Bhaumik, Anand Bardia, Partha S Bhattacharyya, Anisha Gehani, Arpita Bhattacharyya

引用次数: 0

A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium. 来自北美儿科再生障碍性贫血协会的诊断和治疗儿科中度再生障碍性贫血的提供者实践调查。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-15 DOI: 10.1097/MPH.0000000000003209

Linah Omer, Nicholas J Gloude, Catherine McGuinn, Taizo A Nakano, Kathleen Overholt, Elizabeth Ogando-Rivas, Kasiani C Myers, Larisa A Broglie, Kirsty Hillier, Edo Schaefer, Jennifer A Rothman, Sasidhar Goteti, Yigal Dror, María I Cancio, Gloria P Contreras Yametti, Michaela Cada, Kristin A Shimano, Steven W Allen, Jeffrey M Lipton, Peter Kurre, Paul Castillo, Jill L O de Jong

{"title":"A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium.","authors":"Linah Omer, Nicholas J Gloude, Catherine McGuinn, Taizo A Nakano, Kathleen Overholt, Elizabeth Ogando-Rivas, Kasiani C Myers, Larisa A Broglie, Kirsty Hillier, Edo Schaefer, Jennifer A Rothman, Sasidhar Goteti, Yigal Dror, María I Cancio, Gloria P Contreras Yametti, Michaela Cada, Kristin A Shimano, Steven W Allen, Jeffrey M Lipton, Peter Kurre, Paul Castillo, Jill L O de Jong","doi":"10.1097/MPH.0000000000003209","DOIUrl":"10.1097/MPH.0000000000003209","url":null,"abstract":"Pediatric moderate aplastic anemia (MAA) lacks defined diagnostic criteria and a clear standard of care due to limited understanding of its pathophysiology and natural history. To understand current diagnostic and management practices for pediatric patients with MAA, a survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC) was conducted among 104 providers across 57 institutions. The survey results show that the approach to MAA remains inconsistent. The survey demonstrates broad variability regarding the working definition, diagnostic work-up, and therapeutic management of children with MAA. The diagnostic work-up and treatment options for children with MAA are largely driven by management guidelines for pediatric severe aplastic anemia (SAA). Treatment triggers and preferred therapy types varied widely among respondents. Curated next-generation sequencing panels and whole exome/whole genome sequencing were included by only 55% and 9% of respondents, respectively, suggesting the need to more broadly consider inherited bone marrow failure syndromes in the differential diagnosis of these patients. Based on the most commonly reported practices across NAPAAC institutions, we have included a proposed diagnostic and management algorithm in this manuscript. Effective, risk-adapted treatment for children with MAA requires a better understanding of the biology, natural history, and treatment outcomes in this heterogeneous population.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"230-236"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Treatment of Relapsed Pediatric Central Nervous System ALK+ Anaplastic Large Cell Lymphoma With Lorlatinib Monotherapy. Lorlatinib单药成功治疗复发性小儿中枢神经系统ALK+间变性大细胞淋巴瘤。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-11 DOI: 10.1097/MPH.0000000000003224

Courtney M Vaughn, Catherine Evers Smith, Laura G Schuettpelz

引用次数: 0

Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia Therapy. 儿童b细胞急性淋巴细胞白血病治疗中补充免疫球蛋白的做法和效果。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-04-27 DOI: 10.1097/MPH.0000000000003203

Holly J Edington, Nicholas P DeGroote, Jason Stevenson, Shanmuganathan Chandrakasan, Tamara P Miller, Sharon M Castellino

{"title":"Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia Therapy.","authors":"Holly J Edington, Nicholas P DeGroote, Jason Stevenson, Shanmuganathan Chandrakasan, Tamara P Miller, Sharon M Castellino","doi":"10.1097/MPH.0000000000003203","DOIUrl":"10.1097/MPH.0000000000003203","url":null,"abstract":"Although some children with B-cell acute lymphoblastic leukemia (B-ALL) receive intravenous immunoglobulin (IVIG) during conventional therapy, supplementation practices vary, and data describing the indications and their impact are lacking. In this single-institution cohort of children with B-ALL receiving conventional chemotherapy, we evaluate associations of patient and disease characteristics with IVIG supplementation, describe infection-related outcomes by IVIG receipt, and describe outcomes after IVIG supplementation. Multivariable logistic regression models identified factors associated with IVIG receipt. Of 373 eligible patients with B-ALL who did not receive immune therapy, 251 (67.3%) had an IgG level checked, and 114 (30.6%) received IVIG. The median IgG nadir was lower in IVIG recipients versus nonrecipients (404 vs. 675 mg/dL, P<0.01). IVIG recipients were younger at diagnosis (4 vs. 6 y, P<0.01) and had a larger number of severe infections per 1000 leukemia treatment days (4.2 vs. 2.5, P<0.01). In adjusted models, the odds of IVIG administration were lower for non-white patients (OR=0.43, 95% CI=0.22-0.83), higher for patients with >2 severe infections during treatment (OR=2.57, 95% CI=1.28-5.18), and higher for National Cancer Institute standard risk patients with IgG nadir <500 mg/dL (OR=7.45, 95% CI=3.54-15.70). For IVIG recipients, the rate of emergency department visits, severe infections, and febrile neutropenia episodes was 5.4, 1.9, and 1.1 per 1000 treatment days, respectively, during IVIG supplementation. Among children with B-ALL receiving conventional chemotherapy, clinical characteristics differ between IVIG recipients and nonrecipients. Uniform IgG measurements during therapy may guide supplementation decisions, especially in the era of frontline immunotherapy.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":"48 5","pages":"e175-e182"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia is Associated With Overall Survival. 小儿b淋巴细胞白血病初始脑脊液清除率与总生存率相关

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-04-21 DOI: 10.1097/MPH.0000000000003207

Haley Hultquist, Alyssa Rodriguez, My H Vu, Paul S Gaynon, Alexandra E Kovach

{"title":"Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia is Associated With Overall Survival.","authors":"Haley Hultquist, Alyssa Rodriguez, My H Vu, Paul S Gaynon, Alexandra E Kovach","doi":"10.1097/MPH.0000000000003207","DOIUrl":"10.1097/MPH.0000000000003207","url":null,"abstract":"Children with central nervous system (CNS) involvement by B-lymphoblastic leukemia (B-ALL) at diagnosis have higher risk features and greater rates of relapse than those without CNS involvement. This study sought to elucidate the relationship between cerebrospinal fluid (CSF) blast clearance rate with overall survival (OS) and relapse in pediatric B-ALL. Patients with CNS involvement of newly diagnosed B-ALL were stratified into 3 CSF clearance groups by days after initial lumbar puncture: fast (1 to 7 d), intermediate (8 to 15 d), and slow (15+ d) clearers. Among 246 new patients, 28% (69) were CSF+ at diagnosis (87% [60] CNS2, 13% [9] CNS3); 55% (38) fast, 35% (24) intermediate, and 10% (7) slow clearers. The hazard ratio for OS was 5.8 (95% CI: 1.2- 27.9, P =0.029) times higher in slow clearers compared with fast clearers, and 17.4 times higher compared with intermediate clearers (95% CI: 1.7-178, P =0.016). There were no significant differences in risk group ( P =0.3) or relapse rates ( P =0.5). These data suggest that among pediatric patients with CNS+ B-ALL disease at diagnosis, those who cleared CSF faster had better OS compared with patients who were slower at clearing the CSF of blasts. A study of the functional dynamics of underlying differences in CSF clearance rates may inform therapeutic modification.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"237-241"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Excellent Outcome of Residual Pulmonary Metastases in Initially High Burden Metastatic Hepatoblastoma: A Case Series. 最初高负荷转移性肝母细胞瘤残余肺转移的良好预后：一个病例系列。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-04-06 DOI: 10.1097/MPH.0000000000003197

Aviv Sever, Tomer Portnoy, Michael Gurevich, Yuri Paschovich, Shira Amar, Helen Toledano

引用次数: 0

Beacon Bootcamp: A Near-Peer, Experiential Approach to Chemotherapy Prescribing Education in Pediatric Hematology/Oncology Fellowship. 灯塔训练营：儿童血液学/肿瘤学化疗处方教育的近同行经验方法。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-18 DOI: 10.1097/MPH.0000000000003211

Paula Sulikowski, Jennifer C Yu

{"title":"Beacon Bootcamp: A Near-Peer, Experiential Approach to Chemotherapy Prescribing Education in Pediatric Hematology/Oncology Fellowship.","authors":"Paula Sulikowski, Jennifer C Yu","doi":"10.1097/MPH.0000000000003211","DOIUrl":"10.1097/MPH.0000000000003211","url":null,"abstract":"Pediatric hematology/oncology fellows at our institution lacked formal training in prescribing chemotherapy and supportive care. This pilot study aimed to assess the feasibility of implementing a structured curriculum in a fellowship program and to gain preliminary insights into its impact on fellows' confidence and competence in placing chemotherapy and supportive care orders in the Epic Beacon system. We developed Beacon Bootcamp using Kern 6-Step Approach to Curriculum Development. General and targeted needs assessments informed the learning objectives. We held individual practice sessions, grounded in Kolb experiential learning theory, as one of our educational strategies and piloted a near-peer teaching model. The curriculum was implemented during the 2024 to 2025 academic year, and outcomes were compared with a baseline cohort from the prior academic year. Fellows who participated in Beacon Bootcamp reported higher levels of comfort with prescribing chemotherapy and supportive care compared with the previous cohort, which did not receive formal training. We observed a lower rate of order corrections required following the intervention (21% vs. 38%); however, the small sample size limited statistical analysis. Our findings suggest that Beacon Bootcamp improves fellows' confidence and may reduce prescribing errors. Its impact could be greater if implemented during the first quarter of the fellowship. Further evaluation in a larger cohort is needed to more definitively assess its effectiveness.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e150-e154"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset. 遗传性血小板功能障碍的出血表型：来自ATHNdataset的见解。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-19 DOI: 10.1097/MPH.0000000000003213

Divyaswathi Citla-Sridhar, Jianzhong Hu, Robert F Sidonio, Sanjay Ahuja

{"title":"Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.","authors":"Divyaswathi Citla-Sridhar, Jianzhong Hu, Robert F Sidonio, Sanjay Ahuja","doi":"10.1097/MPH.0000000000003213","DOIUrl":"10.1097/MPH.0000000000003213","url":null,"abstract":"Background: Inherited platelet function disorders (IPFDs) are rare, heterogeneous conditions that pose diagnostic and management challenges. While bleeding in Glanzmann thrombasthenia (GT) and Bernard-Soulier syndrome (BSS) is well characterized, milder or unclassified IPFDs remain poorly defined.Objective: To characterize the bleeding phenotype, treatment patterns, and diagnostic distribution of IPFDs across the United States using the national ATHNdataset.Methods: We conducted a retrospective cohort study using the ATHNdataset, a deidentified registry maintained by the American Thrombosis and Hemostasis Network. Clinical outcomes, including bleeding events, laboratory data, treatments, and procedures, were analyzed for participants with IPFDs between 2013 and 2022 and with active follow-up from January 2021 to December 2022.Results: Among 2302 individuals with IPFDs, 8.1% as GT, 2.4% as BSS, 7.0% as granule defects, and 81.6% as IPFD-other. Among 985 participants with active follow-up, 236 bleeding events were reported across 251 patients. The most common events were epistaxis (42.8%), followed by soft tissue (14.4%) and oral bleeding (13.9%). Notably, intracranial hemorrhage occurred in 8 patients and joint bleeds in 82, reflecting significant morbidity across all subtypes. Median ISTH-BAT scores were elevated-13 in GT, 16 in dense-granule defects, and 7 in unclassified IPFDs-exceeding reported population norms. Regarding hemostatic management, antifibrinolytics were used in over half of all patients, with desmopressin and platelet transfusions being used less frequently.Conclusion: By defining the clinical spectrum, treatment utilization, and residual diagnostic uncertainty across IPFDs, this study underscores the importance of improving diagnostic precision and care for patients with platelet function disorders in the modern era.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"207-216"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-Dose Intravitreal Topotecan for Retinoblastoma With Subretinal Seeds: A Well-Tolerated and Efficacious Approach. 高剂量玻璃体内拓扑替康治疗视网膜母细胞瘤：一种耐受性良好且有效的方法。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-01 DOI: 10.1097/MPH.0000000000003221

Ranveer Palia, Waylon Alvarado, Kerri Becktell, Aparna Ramasubramanian, Nicole Liberio

引用次数: 0

Checkpoint Inhibitor Pneumonitis With Pneumomediastinum Following Nivolumab-AVD in Classic Hodgkin Lymphoma: A Case Report. 经典霍奇金淋巴瘤中尼伏单抗- avd后检查点抑制剂肺炎合并纵隔气肿一例报告。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-11 DOI: 10.1097/MPH.0000000000003220

Siddarth R Ganesh, Aaron D Hodes, Burton E Appel

引用次数: 0